These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9211190)

  • 1. Clinical expression, genetics and therapy of adenosine deaminase (ADA) deficiency.
    Hershfield MS; Arredondo-Vega FX; Santisteban I
    J Inherit Metab Dis; 1997 Jun; 20(2):179-85. PubMed ID: 9211190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
    Hershfield MS
    Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies.
    Grunebaum E; Cohen A; Roifman CM
    Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):630-8. PubMed ID: 24113229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles.
    Arredondo-Vega FX; Santisteban I; Daniels S; Toutain S; Hershfield MS
    Am J Hum Genet; 1998 Oct; 63(4):1049-59. PubMed ID: 9758612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adenosine deaminase (ADA) deficiency, partial ADA deficiency].
    Sakiyama Y
    Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):454-7. PubMed ID: 9590099
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency.
    Blackburn MR; Datta SK; Kellems RE
    J Biol Chem; 1998 Feb; 273(9):5093-100. PubMed ID: 9478961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gene therapy for genetic disorders of purine metabolism].
    Hidaka Y
    Nihon Rinsho; 1996 Dec; 54(12):3374-8. PubMed ID: 8976123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-Adenosylhomocysteine hydrolase activity in a lymphoblastoid cell line from a patient with adenosine deaminase dificiency disease.
    Tsuchiya S; Nakae S; Konno T; Tada K
    J Inherit Metab Dis; 1981; 4(4):197-201. PubMed ID: 6796770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New models for the study of adenosine deaminase deficiency.
    Thompson LF
    Adv Exp Med Biol; 1998; 431():447-9. PubMed ID: 9598108
    [No Abstract]   [Full Text] [Related]  

  • 11. Inherited disorders of purine metabolism--underlying molecular mechanisms.
    Gutensohn W
    Klin Wochenschr; 1984 Oct; 62(20):953-62. PubMed ID: 6209448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunodeficiency disease: an inborn error of purine metabolism.
    Pollara B; Moore JJ; Pickering RJ; Gabrielsen AE; Meuwissen HJ
    Birth Defects Orig Artic Ser; 1975; 11(1):120-3. PubMed ID: 1148376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives in the diagnosis and treatment of adenosine deaminase (ADA) deficiency.
    Levinsky RJ; Davies EG; Simmonds HA; Webster DR; Adinolfi M
    Adv Exp Med Biol; 1984; 165 Pt A():33-8. PubMed ID: 6609527
    [No Abstract]   [Full Text] [Related]  

  • 14. Genotype is an important determinant of phenotype in adenosine deaminase deficiency.
    Hershfield MS
    Curr Opin Immunol; 2003 Oct; 15(5):571-7. PubMed ID: 14499267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete adenosine deaminase (ADA) deficiency without immunodeficiency, and primary hyperoxaluria, in a 12-year-old boy.
    Perignon JL; Hamet M; Cartier P; Griscelli C
    Adv Exp Med Biol; 1980; 122A():403-8. PubMed ID: 6968500
    [No Abstract]   [Full Text] [Related]  

  • 16. Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination.
    Gangi-Peterson L; Sorscher DH; Reynolds JW; Kepler TB; Mitchell BS
    J Clin Invest; 1999 Mar; 103(6):833-41. PubMed ID: 10079104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene replacement therapy for inborn errors of purine metabolism.
    Nelson DL; Chang SM; Henkel-Tigges J; Wager-Smith K; Belmont JW; Caskey CT
    Cold Spring Harb Symp Quant Biol; 1986; 51 Pt 2():1065-71. PubMed ID: 3555977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.
    Muul LM; Tuschong LM; Soenen SL; Jagadeesh GJ; Ramsey WJ; Long Z; Carter CS; Garabedian EK; Alleyne M; Brown M; Bernstein W; Schurman SH; Fleisher TA; Leitman SF; Dunbar CE; Blaese RM; Candotti F
    Blood; 2003 Apr; 101(7):2563-9. PubMed ID: 12456496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine deaminase activity in a series of 19 patients with the Diamond-Blackfan syndrome.
    Whitehouse DB; Hopkinson DA; Pilz AJ; Arredondo FX
    Adv Exp Med Biol; 1986; 195 Pt A():85-92. PubMed ID: 3728189
    [No Abstract]   [Full Text] [Related]  

  • 20. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
    Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
    J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.